Evidence map›Paper›PMID 25809305›Full record

ArticleNeurology2015

Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?

Bibiana Bielekova, Michael P McDermott

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Outcomes in Previously Healthy Cryptococcal Meningoencephalitis Patients Treated With Pulse Taper Corticosteroids for Post-infectious Inflammatory Syndrome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  4. Biomarkers in Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019
    Review
  5. Article
  6. Multiple sclerosis: genetics, biomarkers, treatments.Current opinion in neurology · 2016
    Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Bibiana BielekovaFrom The Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Biostatistics and Computational Biology (M.P.M.), University of Rochester Medical Center, NY. bibi.bielekova@nih.gov.
Michael P McDermottFrom The Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Biostatistics and Computational Biology (M.P.M.), University of Rochester Medical Center, NY.

Funding

Comprehensive multimodal analysis of patients with neuroimmunological diseasesZIANS003055 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI BIELEKOVA, BIBIANA · 2009 to 2018
$9.0M
Intramural NIH HHS
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Intermediate FilamentsNeurofibrilsFemaleHumansImmunosuppressive AgentsMaleMultiple Sclerosis, Relapsing-RemittingPropylene GlycolsSphingosineImmunosuppressive AgentsPropylene GlycolsSphingosine

Identifiers

PMID25809305

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.